PsychedelicNewsBreaks Archive - Page 52 of 68

WednesdayApr 14, 2021 12:19 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Prepares to Commence Retail Sales of Gummie Products

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it has commenced production on approximately 50,000 Pure Chews edible gummie packs. Demand for these types of products is strong in the four provinces (British Columbia, Alberta, Saskatchewan and Ontario) that Pure Extracts is targeting for its retail launch, with approximately $200,000 in revenue estimates associated with this batch. All Pure Chews SKUs, including the 10 mg THC packs of Fire Burst, Strawberry and Mango, utilize a proprietary manufacturing system licensed from…

TuesdayApr 13, 2021 10:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of the required U.S. Food and Drug Administration (“FDA”) enabling trials for investigational new drug applications (“INDs”). The results of the studies will be included in the submissions to the FDA and other regulatory bodies, including Health Canada and European Medical Association (“EMA”). The proprietary Cybin…

FridayApr 09, 2021 9:23 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Strategic Equity Investment in Psychedelic Journey Center

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology for psychedelic therapy, has announced a follow-up strategic equity investment in ATMC Journey Centers Inc. ("ATMA"), the first government-approved psychedelic journey center in Canada. Earlier this year, MCUR had signed a letter of intent, securing 13% ownership in ATMA; this additional investment retains that ownership. In addition, the company named Mind Cure Health president and CEO Kelsey Ramsden to the ATMA board of directors. MINDCURE’s investment into the pioneering psychedelic journey center is meant to facilitate the use of iSTRYM (“iSTRYM”), which is MCUR’s proprietary…

ThursdayApr 08, 2021 9:57 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Plans to Launch 1st US Initiative into Dynamic Michigan Market

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced its entry into a letter of intent (“LOI”) with the affiliate of a publicly traded multistate operator (“MSO”) to form a joint venture (the “JV”) to install a cannabis and hemp extraction system in an existing Michigan facility. According to the update, the MSO has a long history of success in Oregon, offering a family of products that include sun-grown and indoor premium flower, along with patented nitro-sealed indoor and sun-grown pre-rolls and…

WednesdayMar 31, 2021 10:52 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa, calls for the development of high-class techniques for the extraction of psilocybin from psychedelic mushrooms as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and…

TuesdayMar 30, 2021 9:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial…

WednesdayMar 24, 2021 2:23 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech…

MondayMar 22, 2021 10:41 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology for the delivery of its novel deuterated tryptamine (“CYB003”), a potential therapy for treatment-resistant psychiatric disorders. “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of…

WednesdayMar 17, 2021 11:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…

WednesdayMar 17, 2021 9:49 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Subsidiary Has Ordered First Shipment of Functional Mushrooms

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) subsidiary Pure Mushrooms Corp. has placed its first order for functional mushrooms from a British Columbia co-packer. Pure Mushrooms will use the mushrooms to produce three products, which will be offered through the company’s online e-commerce store. Previously Pure Mushrooms had developed three premium formulations based on reishi, maitake and lion’s mane mushrooms. These formulations, which are delivered in convenient vegan capsules, will be the foundation of the upcoming new products. Rreishi and maitake formulations should go on sale in April, with the lion’s mane release slated for June. The announcement…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks